May 13, 2020 05:05 PM EDTUpdated May 14, 06:13 AM

Days after rapid FDA approval, Lilly and Blueprint go head-to-head again at ASCO

Eli Lilly may have gotten ahead of Blueprint with an approval last week, but it looks like the Big Pharma and the Cambridge biotech …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Days af­ter rapid FDA ap­proval, Lil­ly and Blue­print go head-to-head again at AS­CO